OTLK Outlook Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
14:43
Jan 06
Jan 06
Cash-poor balance sheet likely forces dilutive financing.
Outlook Therapeutics has $11m cash and receivables against $46m in current debt/payables due this year and no meaningful revenue. The author expects dilution as the company attempts to stay afloat, likely within 6-12 months.
HIGH
08:15
Jan 05
Jan 05
Oversold after FDA denial; correction almost certain; long entry.
The author claims ONS-5010 (LYTENAVA) is approved in Europe and UK for wet-AMD, a market estimated at $10-12B annually, and the recent FDA denial caused a 70-80% price drop that is a massive oversell. He expects a near-term correction and sees a great entry for long-term investors at current cheap prices. Primary risks stated are company financials, dilution risk, and poor cash runway.
HIGH
13:46
Jan 02
Jan 02
Avoid OTLK on weak liquidity and dilution risk.
Author warns OTLK has only $11m cash and receivables against $46 million in current debt/payables due this year, with no revenue to speak of. Dilution is likely, making the shares unattractive.
HIGH
About OTLK Investor Commentary
Across the available history and selected sources, Buzzberg tracks OTLK (Outlook Therapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 33% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: u/No_Cell6708, u/LazyBondar.